On November 1, 2024, Cristian Luput, Director at MAIA Biotechnology Inc (MAIA, Financial), purchased 22,133 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns 389,483 shares of MAIA Biotechnology Inc.
MAIA Biotechnology Inc is focused on the development of targeted therapies for cancer, aiming to address unmet needs in the treatment of the disease. The company's strategic approach leverages novel technologies to create therapies that are intended to be both effective and minimally invasive.
Over the past year, Cristian Luput has increased his holdings in the company significantly, purchasing a total of 91,415 shares. There have been no sales recorded by the insider during this period. The recent acquisition was executed at a stock price of $2.51, valuing the transaction at approximately $55,574.83.
The market cap of MAIA Biotechnology Inc stands at $69.027 million. The company's stock valuation metrics, such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are accessible for further details on the company's financial health and stock valuation.
Insider transaction trends for MAIA Biotechnology Inc show a positive sentiment, with 11 insider buys and no insider sells over the past year. This pattern of insider purchases may indicate a bullish outlook on the company's future by those closest to its operations.
For more detailed information on the valuation of MAIA Biotechnology Inc, interested parties can refer to the GF Value of the stock.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
